Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of th...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 19; no. 11; pp. 1480 - 1492
Main Authors:	Hodi, Frank Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Cowey, Charles Lance, Lao, Christopher D, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier Francesco, Smylie, Michael, Hill, Andrew, Hogg, David, Marquez-Rodas, Ivan, Jiang, Joel, Rizzo, Jasmine, Larkin, James, Wolchok, Jedd D
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.11.2018 Elsevier Limited
Subjects:	Cardiomyopathy Colitis Colon Diarrhea Hematology, Oncology, and Palliative Medicine Immunotherapy Intravenous administration Lipase Liver Melanoma Metastases Metastasis Monoclonal antibodies Motivation Mutation Neutropenia Oncology Patients PD-L1 protein Regulatory approval Studies Survival Targeted cancer therapy United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!